----

|  | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--|---------|--------------------------------------------------------------------------------------|
|  | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--|---------|------------------------------------------------------------------------------------------|
| Delaware                                                       |   | 85-2754095                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|                                              |   |       |
|---------------------------------------------------|--------|------------|
| 7809 Woodmont Avenue, Suite 200Bethesda, Maryland |   | 20814      |
| (Address of principal executive offices)          |   | (Zip Code) |
| Title of each class                                                                                                                |   | Trading Symbol |   | Name of each exchange on which registered |
|------------------------------------------------------------------------------------------------------------------------------------|--------|----------------|--------|-------------------------------------------|
|                                                                                                                               |   |           |   |                                      |
| Units, each consisting of one share of Class A Common Stock and one-half of one redeemable warrant                                 |   | HCARU          |   | The Nasdaq Stock Market LLC               |
|                                                                                                                               |   |           |   |                                      |
| Class A Common Stock, par value $0.0001 per share                                                                                  |   | HCAR           |   | The Nasdaq Stock Market LLC               |
|                                                                                                                               |   |           |   |                                      |
| Redeemable Warrants, each whole Warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share |   | HCARW          |   | The Nasdaq Stock Market LLC               |
| ☐ Yes ☒ No | Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.      |
|------------------------|------------------------------------------------------------------------------------------------------------------------------|
|                   |                                                                                                                         |
| ☐ Yes ☒ No | Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. |
| Large accelerated filer | Accelerated filer | Non‐accelerated filer | Smaller reporting company | Emerging growth company |
|-------------------------|-------------------|-----------------------------|---------------------------|-------------------------|
| ☐                 | ☐           | ☒                     | ☒                   | ☒                 |

----

----

| PART I   | 6        |
|----------|----------|
|     |     |
|     | Item 1.  | Business | 6 |
|     |     |   |   |
|     | Item 1A. | Risk Factors | 18 |
|     |     |   |   |
|     | Item 1B. | Unresolved Staff Comments | 52 |
|     |     |   |   |
|     | Item 2.  | Properties | 52 |
|     |     |   |   |
|     | Item 3.  | Legal Proceedings | 52 |
|     |     |   |   |
|     | Item 4.  | Mine Safety Disclosures | 52 |
|     |     |   |   |
| PART II  | 53       |
|     |     |
|     | Item 5.  | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities | 53 |
|     |     |   |   |
|     | Item 6.  | Selected Financial Data | 54 |
|     |     |   |   |
|     | Item 7.  | Management’s Discussion and Analysis of Financial Condition and Results of Operations (Restated) | 54 |
|     |     |   |   |
|     | Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 60 |
|     |     |   |   |
|     | Item 8.  | Financial Statements and Supplementary Data (Restated) | 60 |
|     |     |   |   |
|     | Item 9.  | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 60 |
|     |     |   |   |
|     | Item 9A. | Controls and Procedures (Restated) | 61 |
|     |     |   |   |
|     | Item 9B. | Other Information | 61 |
|     |     |   |   |
| PART III | 62       |
|     |     |
|     | Item 10. | Directors, Executive Officers, and Corporate Governance | 62 |
|     |     |   |   |
|     | Item 11. | Executive Compensation | 66 |
|     |     |   |   |
|     | Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 67 |
|     |     |   |   |
|     | Item 13. | Certain Relationships and Related Transactions, and Director Independence | 69 |
|     |     |   |   |
|     | Item 14. | Principal Accountant Fees and Services | 71 |
|     |     |   |   |
| PART IV  | 72       |
|     |     |
|     | Item 15. | Exhibits and Financial Statement Schedules | 72 |
|     |     |   |   |
|     | Item 16. | Form 10-K Summary | 73 |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | our being a company with no operating history and no revenues; |
|--|---------|----------------------------------------------------------------|
|  | • | our ability to select an appropriate target business or businesses; |
|--|---------|---------------------------------------------------------------------|
|  | • | our ability to complete our initial business combination, particularly given competition from other blank check companies and financial and strategic buyers; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our expectations around the performance of the prospective target business or businesses, including competitive prospects of the business following our initial business combination; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they              would then receive expense reimbursements; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our potential ability to obtain additional financing to complete our initial business combination; |
|--|---------|----------------------------------------------------------------------------------------------------|
|  | • | the number, variety and characteristics of prospective target businesses; |
|--|---------|---------------------------------------------------------------------------|
|  | • | our ability to consummate an initial business combination amidst the uncertainty resulting from the ongoing COVID-19 pandemic, and the effects of the ongoing pandemic on the healthcare industry, the economy and              any business or businesses with which we consummate our initial business combination; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | the ability of our officers and directors to generate a number of potential acquisition opportunities; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | our public securities’ potential liquidity and trading; |
|--|---------|---------------------------------------------------------------|
|  | • | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------|
|  | • | the trust account not being subject to claims of third parties; |
|--|---------|-----------------------------------------------------------------|
|  | • | our financial performance; and |
|--|---------|--------------------------------|
|  | • | the other risks and uncertainties discussed in “Risk Factors” and elsewhere in this prospectus. |
|--|---------|-------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 1. | Business |
|---------|----------|

----

Table of Contents

----

Table of Contents

|  | • | Driving cost and margin efficiencies |
|--|---------|--------------------------------------|
|  | • | Enabling the company to participate in previously out-of-reach growth opportunities |
|--|---------|-------------------------------------------------------------------------------------|
|  | • | Improving excess cash flow to facilitate superior capital allocation |
|--|---------|----------------------------------------------------------------------|
|  | • | Feeding a virtuous cycle of multiple expansion in public markets |
|--|---------|------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | Traditional due diligence. We will conduct a thorough due diligence review which will encompass, among other things:                meetings with incumbent management and employees; document reviews; inspection of facilities; as well as a review of financial, operational, legal and other information which will be made available to us. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Strategic business plan build. We will work hand-in-hand with incumbent management to jointly build a strategic business plan in order to guide the company’s growth, operations, and strategy following a              business combination. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Established companies with good reputations and track records, but meaningful opportunities for strategic repositioning and operational improvements |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Growth prospects constrained by capital availability, operational expertise and national-scale capabilities, where the provision of one or more would enable participation in previously off-limits commercial              opportunities |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Reliable demand profile that would drive recurring revenue |
|--|---------|------------------------------------------------------------|
|  | • | Significant untapped white space in home or adjacent markets |
|--|---------|--------------------------------------------------------------|
|  | • | Competitive advantage relative to other players |
|--|---------|-------------------------------------------------|
|  | • | Appropriate valuation |
|--|---------|-----------------------|
|  | • | Benefits from being a public company |
|--|---------|--------------------------------------|
|  | • | Ambitious management who welcome our capital and the involvement of our management team as a growth enabler |
|--|---------|-------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the              redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | file proxy materials with the SEC. |
|--|---------|------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 1A. | Risk Factors. |
|----------|---------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | restrictions on the nature of our investments; and |
|--|---------|----------------------------------------------------|
|  | • | restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------|
|  | • | registration as an investment company; |
|--|---------|----------------------------------------|
|  | • | adoption of a specific form of corporate structure; and |
|--|---------|---------------------------------------------------------|
|  | • | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
|--|---------|-------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | may significantly dilute the equity interest of existing investors; |
|--|---------|---------------------------------------------------------------------|
|  | • | may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and              could result in the resignation or removal of our present officers and directors; and |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may adversely affect prevailing market prices for our Units, Class A common stock and/or warrants. |
|--|---------|----------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or              reserves without a waiver or renegotiation of that covenant; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our inability to pay dividends on our common stock; |
|--|---------|-----------------------------------------------------|
|  | • | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make              capital expenditures and acquisitions, and fund other general corporate purposes; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements and execution of our strategy; and |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | other disadvantages compared to our competitors who have less debt. |
|--|---------|---------------------------------------------------------------------|
|  | • | solely dependent upon the performance of a single business, property or asset, or |
|--|---------|-----------------------------------------------------------------------------------|
|  | • | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | a limited availability of market quotations for our securities; |
|--|---------|-----------------------------------------------------------------|
|  | • | reduced liquidity for our securities; |
|--|---------|---------------------------------------|
|  | • | a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in a reduced level of              trading activity in the secondary trading market for our securities; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | a limited amount of news and analyst coverage; and |
|--|---------|----------------------------------------------------|
|  | • | a decreased ability to issue additional securities or obtain additional financing in the future. |
|--|---------|--------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | (i) | we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a price (the “Newly Issued              Price”) of less than $9.20 per share; |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | (ii) | the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the              consummation of our initial business combination (net of redemptions); and |
|--|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | (iii) | the Market Value is below $9.20 per share, then the exercise price of the warrants will be adjusted to be equal to 115% of the higher of (i) the volume weighted average trading price of our common stock during              the 20 trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the “Market Value”) and (ii) the Newly Issued Price, and the $18.00 per share redemption trigger              prices will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher              of the Market Value and the Newly Issued Price. |
|--|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | we have a board that includes a majority of “independent directors,” as defined under the rules of Nasdaq; |
|--|---------|------------------------------------------------------------------------------------------------------------------------|
|  | • | we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | we have a nominating and corporate governance committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | higher costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | rules and regulations regarding currency redemption; |
|--|---------|------------------------------------------------------|
|  | • | complex corporate withholding taxes on individuals; |
|--|---------|-----------------------------------------------------|
|  | • | laws governing the manner in which future business combinations may be effected; |
|--|---------|----------------------------------------------------------------------------------|
|  | • | tariffs and trade barriers; |
|--|---------|-----------------------------|
|  | • | regulations related to customs and import/export matters; |
|--|---------|-----------------------------------------------------------|
|  | • | longer payment cycles and challenges in collecting accounts receivable; |
|--|---------|-------------------------------------------------------------------------|
|  | • | tax issues, including but not limited to tax law changes and variations in tax laws as compared to the United States; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------|
|  | • | currency fluctuations and exchange controls; |
|--|---------|----------------------------------------------|
|  | • | rates of inflation; |
|--|---------|---------------------|
|  | • | cultural and language differences; |
|--|---------|------------------------------------|
|  | • | employment regulations; |
|--|---------|-------------------------|
|  | • | data privacy; |
|--|---------|---------------|
|  | • | changes in industry, regulatory or environmental standards within the jurisdictions where we operate; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | public health or safety concerns and governmental restrictions, including those caused by outbreaks of pandemic disease such as the COVID-19 pandemic; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars; |
|--|---------|-------------------------------------------------------------------------------------------|
|  | • | deterioration of political relations with the United States; and |
|--|---------|------------------------------------------------------------------|
|  | • | government appropriations of assets. |
|--|---------|--------------------------------------|
|  | • | Competition could reduce profit margins; |
|--|---------|------------------------------------------|
|  | • | Our inability to comply with governmental regulations affecting the healthcare industry could negatively affect our operations; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | An inability to license or enforce intellectual property rights on which our business may depend; |
|--|---------|---------------------------------------------------------------------------------------------------|
|  | • | The success of our planned business following consummation of our initial business combination may depend on maintaining a well-secured business and technology infrastructure; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Continuing government and private efforts to contain healthcare costs, including through the implementation of legal and regulatory changes, may reduce our future revenue and our profitability following an              initial business combination; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Changes in the healthcare related wellness industry and markets for such products affecting our customers or retailing practices could negatively impact customer relationships and our results of operations; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The healthcare services industry is susceptible to significant liability exposure. If liability claims are brought against us following our initial business combination, it could materially adversely affect our              operations; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Dependence of our operations upon third-party suppliers or contractors whose failure to perform adequately could disrupt our business; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The Affordable Care Act, possible changes to it or its repeal, and how it is implemented could negatively impact our business; and |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------|
|  | • | A disruption in supply could adversely impact our business. |
|--|---------|-------------------------------------------------------------|

----

Table of Contents

| Item 1B. | Unresolved Staff Comments |
|----------|---------------------------|
| Item 2. | Properties |
|---------|------------|
| Item 3. | Legal Proceedings |
|---------|-------------------|
| Item 4. | Mine Safety Disclosures |
|---------|-------------------------|

----

Table of Contents

| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities |
|---------|---------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 6. | Selected Financial Data |
|---------|-------------------------|
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|---------|---------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk |
|----------|------------------------------------------------------------|
| Item 8. | Financial Statements and Supplementary Data |
|---------|---------------------------------------------|
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
|---------|--------------------------------------------------------------------------------------|

----

Table of Contents

| Item 9A. | Controls and Procedures |
|----------|-------------------------|
| Item 9B. | Other Information |
|----------|-------------------|

----

Table of Contents

| Item 10. | Directors, Executive Officers, and Corporate Governance |
|----------|---------------------------------------------------------|
| Name                   |   | Age    |   | Title                                             |
|------------------------|--------|--------|--------|---------------------------------------------------|
|                   |   |   |   |                                              |
| David T. Blair         |   | 51     |   | Chief Executive Officer and Chairman of the Board |
| Martin J. Payne        |   | 52     |   | President and Director                            |
| Joshua B. Lynn         |   | 40     |   | Chief Financial Officer                           |
| Tao Tan                |   | 35     |   | Chief Operating Officer                           |
| Michael P. Donovan     |   | 62     |   | Director                                          |
| Brian T. Griffin       |   | 62     |   | Director                                          |
| Jeanne L. Manischewitz |   | 47     |   | Director                                          |

----

Table of Contents

----

Table of Contents

|  | • | the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by us; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | pre-approving all audit and permitted non-audit services to be provided by the independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | setting clear hiring policies for employees or former employees of the independent registered public accounting firm; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------|
|  | • | setting clear policies for audit partner rotation in compliance with applicable laws and regulations; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public accounting firm’s internal quality-control              procedures, (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years              respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues and (iii) all relationships between the independent registered public accounting firm and us to assess the independent registered              public accounting firm’s independence; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including reviewing our specific              disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or              government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the              Financial Accounting Standards Board, the SEC or other regulatory authorities. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, if any is paid by us, evaluating our Chief Executive Officer’s performance              in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and making recommendations on an annual basis to our board of directors with respect to (or approving, if such authority is so delegated by our board of directors) the compensation, if any is paid by              us, and any incentive-compensation and equity-based plans that are subject to board approval of our other officers; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing on an annual basis our executive compensation policies and plans; |
|--|---------|-----------------------------------------------------------------------------|
|  | • | implementing and administering our incentive compensation equity-based remuneration plans; |
|--|---------|--------------------------------------------------------------------------------------------|
|  | • | assisting management in complying with our proxy statement and annual report disclosure requirements; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | if required, producing a report on executive compensation to be included in our annual proxy statement; and |
|--|---------|-------------------------------------------------------------------------------------------------------------|
|  | • | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
|--|---------|----------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 11. | Executive Compensation |
|----------|------------------------|

----

Table of Contents

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|----------|------------------------------------------------------------------------------------------------|
|  | • | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
|--|---------|---------------------------------------------------------------------------------------------------------------|
|  | • | each of our executive officers and directors; and |
|--|---------|---------------------------------------------------|
|  | • | all our executive officers and directors as a group. |
|--|---------|------------------------------------------------------|

----

Table of Contents

|                                                                |   | Class A Common Stock             |      |   | Class B Common Stock(1)       |   |   |                             |   |
|---------------------------------------------------------------------|--------|----------------------------------|-----------|--------|-------------------------------|--------|--------|----------------------------------|--------|
| Name of Beneficial Owner                                            |   | Number ofSharesBeneficiallyOwned |      |   | ApproximatePercentageof Class |   |   | Number ofSharesBeneficiallyOwned |   |   | ApproximatePercentageofClass |   |   | ApproximatePercentageofOutstandingCommonStock |   |
| Healthcare Services Acquisition Holdings LLC(2)(3)                  |   |                             | -         |   |                          |   | -      |                             |   |   | 8,190,000 |   |   |   | 98.9 | % |   |   | 19.8 | % |
| David T. Blair                                                      |   |                             | -         |   |                          |   | -      |                             |   |   | - |   |   |   | - |   |   |   | - |   |
| Martin J. Payne                                                     |   |                             | -         |   |                          |   | -      |                             |   |   | - |   |   |   | - |   |   |   | - |   |
| Joshua B. Lynn                                                      |   |                             | -         |   |                          |   | -      |                             |   |   | - |   |   |   | - |   |   |   | - |   |
| Tao Tan                                                             |   |                             | -         |   |                          |   | -      |                             |   |   | - |   |   |   | - |   |   |   | - |   |
| Michael P. Donovan                                                  |   |                             | -         |   |                          |   | -      |                             |   |   | 30,000 |   |   |   | * |   |   |   | * |   |
| Brian T. Griffin                                                    |   |                             | -         |   |                          |   | -      |                             |   |   | 30,000 |   |   |   | * |   |   |   | * |   |
| Jeanne L. Manischewitz                                              |   |                             | -         |   |                          |   | -      |                             |   |   | 30,000 |   |   |   | * |   |   |   | * |   |
| BlackRock, Inc.(4)                                                  |   |                             | 2,527,576 |   |                          |   | 7.6    | %                                |   |   | - |   |   |   | - |   |   |   | 6.1 | % |
| All executive officers and directors as a group (seven individuals) |   |                             | -         |   |                          |   | -      |                             |   |   | 90,000 |   |   |   | 1.1 | % |   |   | * |   |

----

| * | Less than one percent. |
|---|------------------------|
| (1) | Shares of Class B common stock are convertible into shares of Class A common stock on a one-for-one basis, subject to adjustment. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------|
| (2) | The shares reported above are held in the name of our Sponsor. Our Sponsor is managed by a board of managers consisting of David Blair, Martin Payne and Joshua Lynn. Any action by our Sponsor with respect                  to our company or the shares reported above, including voting and dispositive decisions, requires a majority vote of the managers of the board of managers. Under the so-called “rule of three,” because voting and dispositive decisions are                  made by a majority of our Sponsor's managers, none of the managers of our Sponsor is deemed to be a beneficial owner of our Sponsor's securities, even those in which such manager holds a pecuniary interest. Accordingly, none of our                  officers is deemed to have or share beneficial ownership of the Securities held by our sponsor. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Includes up to 1,320,000 shares of Class B common stock held by our Sponsor that our Sponsor has agreed to sell to our Anchor Investor upon consummation of our initial business combination. See “Certain                  Relationships and Related Party Transactions, and Director Independence.” |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Based on a Schedule 13G filed by BlackRock, Inc. with the SEC on February 8, 2021. The principal business address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 13. | Certain Relationships and Related Transactions, and Director Independence Certain Relationships and Related Transactions |
|----------|--------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | Payment to our Sponsor of $20,000 per month, for up to 24 months, for office space, utilities and administrative support; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------|
|  | • | Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  |  • | Repayment of loans which may be made by our Sponsor or an affiliate of our Sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business                  combination, the terms of which have not been determined nor have any written agreements been executed with respect thereto. Up to $2,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of                  the lender. |
|--|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Item 14. | Principal Accountant Fees and Services |
|----------|----------------------------------------|

----

Table of Contents

| Item 15. | Exhibits and Financial Statement Schedules |
|----------|--------------------------------------------|
| (a) | The following documents are filed as part of this Form 10-K/A: |
|-----|----------------------------------------------------------------|
| (1) | Financial Statements: |
|-----|-----------------------|
|                                                              | Page |
|-------------------------------------------------------------------|------|
| Report of Independent Registered Public Accounting Firm           | F-1  |
| Balance Sheet (As Restated)                                       | F-2  |
| Statement of Operations (As Restated)                             | F-3  |
| Statement of Changes in Stockholder’s Deficit (As Restated) | F-4  |
| Statement of Cash Flows (As Restated)                             | F-5  |
| Notes to Financial Statements (As Restated)                       | F-6  |
| (2) | Financial Statement Schedules: |
|-----|--------------------------------|
| (3) | Exhibits |
|-----|----------|

| Exhibitnumber |   | Description of exhibit                                                                                                                                                                                                                                                                                                                                                    |
|---------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1           |   | Amended and Restated Certificate of Incorporation (incorporated by reference to                      Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                                                                                                      |
| 3.2           |   | Bylaws (incorporated by reference to Exhibit 3.3 to the Company’s Registration                      Statement on Form S-1, filed on December 11, 2020 (File No. 333-249389))                                                                                                                                                                                        |
| 4.1           |   | Warrant Agreement, dated December 22, 2020, between the Company and Continental Stock Transfer &                      Trust Company (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                                     |
| 4.2*          |   | Description of the Company’s Securities                                                                                                                                                                                                                                                                                                                             |
| 10.1          |   | Warrant Purchase Agreement, dated December 22, 2020, between the Company and Healthcare Services                      Acquisition Holdings, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                            |
| 10.2          |   | Investment Management Trust Agreement, dated December 22, 2020, between the Company and Continental                      Stock Transfer & Trust Company (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                |
| 10.3          |   | Registration and Stockholder Rights Agreement, dated December 22, 2020, among the Company, Healthcare                      Services Acquisition Holdings, LLC and the other Holders (as defined therein) signatory thereto (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823)) |
| 10.4          |   | Letter Agreement, dated December 22, 2020, among the Company, Healthcare Services Acquisition                      Holdings, LLC and each of the Company's officers and directors (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                          |
| 10.5          |   | Administrative Services Agreement, dated December 22, 2020, between the Company and Healthcare                      Services Acquisition Holdings, LLC (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                     |
| 10.6+         |   | Form of Indemnification Agreement, dated December 22, 2020, between the Company and each of the                      officers and directors of the Company (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K, filed on December 30, 2020 (File No. 001-39823))                                                                 |
| 24.1          |   | Power of Attorney (included on signature page)                                                                                                                                                                                                                                                                                                                            |

----

Table of Contents

| Exhibitnumber |   | Description of exhibit                                                                                                                                                                                      |
|---------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1*         |   | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and                      15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2*         |   | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and                      15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1**        |   | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section                      906 of the Sarbanes-Oxley Act of 2002                                  |
| 32.2**        |   | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section                      906 of the Sarbanes-Oxley Act of 2002.                                 |

| * | Filed herewith. |
|---|-----------------|
| ** | Furnished herewith |
|----|--------------------|
| + | Indicates a management contract or compensatory plan. |
|---|-------------------------------------------------------|
| Item 16. | Form 10-K Summary |
|----------|-------------------|

----

Table of Contents

|   | By:    | /s/ Joshua B. Lynn             |   |
|--------|--------|--------------------------------|--------|
|   |   | Name: Joshua B. Lynn           |
|   |   | Title: Chief Executive Officer |
| Signature                  |   | Title                                                                        |           | Date           |
|----------------------------|--------|------------------------------------------------------------------------------|----------------|----------------|
|                       |   |                                                                         |           |           |
| /s/ David T. Blair         |   | Chairman of the Board                                                        |           | March 14, 2022 |
| David T. Blair             |   |                                                                         |
|                       |   |                                                                         |           |           |
| /s/ Joshua B. Lynn         |   | Chief Executive Officer (Principal Executive Officer)                        |           | March 14, 2022 |
| Joshua B. Lynn             |   |                                                                         |
|                       |   |                                                                         |           |           |
| /s/ John Stanfield         |   | Chief Financial Officer (Principal Financial Officer and Accounting Officer) |           | March 14, 2022 |
| John Stanfield             |
|                       |   |                                                                         |           |           |
| /s/ Martin J. Payne        |   | President and Director                                                       |           |           |
| Martin J. Payne            |   |                                                                         | March 14, 2022 |
|                       |   |                                                                         |
| /s/ Michael P. Donovan     |   | Director                                                                     |           |           |
| Michael P. Donovan         |   |                                                                         | March 14, 2022 |
|                       |   |                                                                         |
| /s/ Brian T. Griffin       |   |                                                                         |           |           |
| Brian T. Griffin           |   | Director                                                                     |           | March 14, 2022 |
|                       |   |                                                                         |
| /s/ Jeanne L. Manischewitz |   |                                                                         |           |           |
| Jeanne L. Manischewitz     |   | Director                                                                     |           | March 14, 2022 |
|                       |   |                                                                         |

----

Table of Contents

|   |                                                                                                                                        | Page No. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------|----------|
|   |                                                                                                                                        |     |
|   | Report of Independent Registered Public Accounting Firm                                                                                     | F-1      |
|   |                                                                                                                                        |     |
|   | Balance Sheet as of December 31, 2020 (As Restated)                                                                                         | F-2      |
|   |                                                                                                                                        |     |
|   | Statement of Operations for the period from August 26, 2020 (inception) through December 31, 2020 (As Restated)                             | F-3      |
|   |                                                                                                                                        |     |
|   | Statement of Changes in Stockholders’ Deficit for the period from August 26, 2020 (inception) through December 31, 2020 (As Restated) | F-4      |
|   |                                                                                                                                        |     |
|   | Statement of Cash Flows for the period from August 26, 2020 (inception) through December 31, 2020 (As Restated)                             | F-5      |
|   |                                                                                                                                        |     |
|   | Notes to Financial Statements (As Restated)                                                                                                 | F-6      |

----

Table of Contents

----

Table of Contents

| Assets:                                                                                                                                               |   |   |        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------------|
| Current assets:                                                                                                                                       |   |   |        |
| Cash                                                                                                                                                  |   | $      | 922,756     |   |
| Prepaid expenses                                                                                                                                      |   |   | 477,245     |   |
| Total current assets                                                                                                                                  |   |   | 1,400,001   |   |
| Investments held in Trust Account                                                                                                                     |   |   | 331,191,879 |   |
| Total Assets                                                                                                                                          |   |   | 332,591,880 |   |
|                                                                                                                                                  |   |   |        |   |
| Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Deficit:                                                           |   |   |        |   |
| Current liabilities:                                                                                                                                  |   |   |        |   |
| Accounts payable                                                                                                                                      |   | $      | 8,823       |   |
| Accrued expenses                                                                                                                                      |   |   | 78,417      |   |
| Due to related party                                                                                                                                  |   |   | 20,200      |   |
| Franchise tax payable                                                                                                                                 |   |   | 69,091      |   |
| Total current liabilities                                                                                                                             |   |   | 176,531     |   |
| Derivative warrant liabilities                                                                                                                        |   |   | 27,623,040  |   |
| Deferred underwriting commissions                                                                                                                     |   |   | 11,592,000  |   |
| Total Liabilities                                                                                                                                     |   |   | 39,391,571  |   |
|                                                                                                                                                  |   |   |        |   |
| Commitments and Contingencies                                                                                                                         |   |   |        |   |
|                                                                                                                                                  |   |   |        |   |
| Class A common stock subject to possible redemption, $0.0001 par value; 33,120,000 shares issued and outstanding at $10.00 per share redemption value |   |   | 331,200,000 |   |
|                                                                                                                                                  |   |   |        |   |
| Stockholders' Equity:                                                                                                                                 |   |   |        |   |
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding                                                 |   |   | -           |   |
| Class A common stock, $0.0001 par value; 100,000,000 shares authorized; no non-redeemable shares issued or outstanding                                |   |   | -           |   |
| Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 8,280,000 shares issued and outstanding                                        |   |   | 828         |   |
| Additional paid-in capital                                                                                                                            |   |   | -           |   |
| Accumulated deficit                                                                                                                                   |   |   | (38,000,519 | ) |
| Total stockholders' deficit                                                                                                                           |   |   | (37,999,691 | ) |
| Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Deficit                                                      |   | $      | 332,591,880 |   |

----

Table of Contents

| General and administrative expenses                                           |   | $      | 32,967     |   |
|-------------------------------------------------------------------------------|--------|--------|------------|--------|
| General and administrative expenses - related party                           |   |   | 5,807      |   |
| Franchise tax expenses                                                        |   |   | 69,091     |   |
| Total operating expenses                                                      |   |   | (107,865   | )      |
| Loss upon issuance of private placement warrants                              |   |   | (776,160   | )      |
| Change in fair value of derivative warrant liabilities                        |   |   | (338,080   | )      |
| Transaction costs allocated to derivative warrant liabilities                 |   |   | (1,039,365 | )      |
| Loss on investments held in Trust Account                                     |   |   | (8,121     | )      |
| Net loss                                                                      |   | $      | (2,269,591 | )      |
|                                                                          |   |   |       |   |
| Basic and diluted weighted average shares outstanding of Class A common stock |   |   | 1,035,000  |   |
| Basic and diluted net loss per share, Class A common stock                    |   | $      | (0.27      | )      |
| Basic and diluted weighted average shares outstanding of Class B common stock |   |   | 7,233,750  |   |
| Basic and diluted net loss per share, Class B common stock                    |   | $      | (0.27      | )      |

----

Table of Contents

|                                                                    |   | Common Stock |   |   |    |   |   |               |   |   | Total       |   |
|-------------------------------------------------------------------------|--------|--------------|--------|--------|---------|--------|--------|--------------------|--------|--------|-------------|--------|
|                                                                    |   | Class A      |   |   | Class B |   |   | Additional Paid-In |   |   | Accumulated |   |   | Stockholders' |   |
|                                                                    |   | Shares       |   |   | Amount  |   |   | Shares             |   |   | Amount      |   |   | Capital |   |   | Deficit |   |   | Deficit |   |
| Balance - August 26, 2020 (inception)                                   |   |         | -      |   |    | $      | -      |               |   |   | -           |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| Issuance of Class B common stock to Sponsor                             |   |         | -      |   |    |   | -      |               |   |   | 8,280,000   |   |   |   | 828 |   |   |   | 24,172 |   |   |   | - |   |   |   | 25,000 |   |
| Accretion of Class A common stock subject to possible redemption amount |   |         | -      |   |    |   | -      |               |   |   | -           |   |   |   | - |   |   |   | (24,172 | ) |   |   | (35,730,928 | ) |   |   | (35,755,100 | ) |
| Net loss                                                                |   |         | -      |   |    |   | -      |               |   |   | -           |   |   |   | - |   |   |   | - |   |   |   | (2,269,591 | ) |   |   | (2,269,591 | ) |
| Balance - December 31, 2020                                             |   |         | -      |   |    | $      | -      |               |   |   | 8,280,000   |   |   | $ | 828 |   |   | $ | - |   |   | $ | (38,000,519 | ) |   | $ | (37,999,691 | ) |

----

Table of Contents

| Cash Flows from Operating Activities:                                            |   |   |         |
|----------------------------------------------------------------------------------|--------|--------|--------------|
| Net loss                                                                         |   | $      | (2,269,591   | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:      |   |   |         |   |
| Loss upon issuance of private placement warrants                                 |   |   | 776,160      |   |
| Change in fair value of derivative warrant liabilities                           |   |   | 338,080      |   |
| Transaction costs allocated to derivative warrant liabilities                    |   |   | 1,039,365    |   |
| Loss on investments held in Trust Account                                        |   |   | 8,121        |   |
| Changes in operating assets and liabilities:                                     |   |   |         |   |
| Prepaid expenses                                                                 |   |   | (477,245     | ) |
| Accounts payable                                                                 |   |   | 68           |   |
| Accrued expenses                                                                 |   |   | 6,417        |   |
| Due to Related Party                                                             |   |   | 20,200       |   |
| Franchise tax payable                                                            |   |   | 69,091       |   |
| Net cash used in operating activities                                            |   |   | (489,334     | ) |
|                                                                             |   |   |         |   |
| Cash Flows from Investing Activities                                             |   |   |         |   |
| Cash deposited in Trust Account                                                  |   |   | (331,200,000 | ) |
| Net cash used in investing activities                                            |   |   | (331,200,000 | ) |
|                                                                             |   |   |         |   |
| Cash Flows from Financing Activities:                                            |   |   |         |   |
| Proceeds received from note payable to related party                             |   |   | 174,000      |   |
| Repayment of note payable to related party                                       |   |   | (174,000     | ) |
| Proceeds from issuance of Class B common stock to Sponsor                        |   |   | 25,000       |   |
| Proceeds received from initial public offering, gross                            |   |   | 331,200,000  |   |
| Proceeds received from private placement                                         |   |   | 8,624,000    |   |
| Offering costs paid                                                              |   |   | (7,236,910   | ) |
| Net cash provided by financing activities                                        |   |   | 332,612,090  |   |
|                                                                             |   |   |         |   |
| Net increase in cash                                                             |   |   | 922,756      |   |
|                                                                             |   |   |         |   |
| Cash - beginning of the period                                                   |   |   | -            |   |
| Cash - end of the period                                                         |   | $      | 922,756      |   |
|                                                                             |   |   |         |   |
| Supplemental disclosure of noncash activities:                                   |   |   |         |   |
| Offering costs included in accrued expenses                                      |   | $      | 72,000       |   |
| Offering costs included in accounts payable                                      |   | $      | 8,755        |   |
| Deferred underwriting commissions in connection with the initial public offering |   | $      | 11,592,000   |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| As of December 31, 2020                                                                                   |   | As Reported AsPreviouslyRestated in10-K/AAmendmentNo. 1 |        |   | Adjustment |   |        | As Restated |   |
|-----------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|-------------|--------|------------|--------|-------------|-------------|--------|
| Total assets                                                                                              |   | $                                                       | 332,591,880 |   |       | $      | -           |        |   | $ | 332,591,880 |   |
| Total liabilities                                                                                         |   | $                                                       | 39,391,571  |   |       | $      | -           |        |   | $ | 39,391,571 |   |
| Class A common stock subject to possible redemption                                                       |   |                                                    | 288,200,300 |   |       |   | 42,999,700  |        |   |   | 331,200,000 |   |
| Preferred stock                                                                                           |   |                                                    | -           |   |       |   | -           |        |   |   | - |   |
| Class A common stock                                                                                      |   |                                                    | 430         |   |       |   | (430        | )           |   |   | - |   |
| Class B common stock                                                                                      |   |                                                    | 828         |   |       |   | -           |        |   |   | 828 |   |
| Additional paid-in capital                                                                                |   |                                                    | 7,268,342   |   |       |   | (7,268,342  | )           |   |   | - |   |
| Accumulated deficit                                                                                       |   |                                                    | (2,269,591  | )      |       |   | (35,730,928 | )           |   |   | (38,000,519 | ) |
| Total stockholders' equity (deficit)                                                                      |   |                                                    | 5,000,009   |   |       |   | (42,999,700 | )           |   |   | (37,999,691 | ) |
| Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit) |   | $                                                       | 332,591,880 |   |       | $      | -           |        |   | $ | 332,591,880 |   |
| For the period from August 26, 2020 (inception) through December 31, 2020 |   |
|---------------------------------------------------------------------------|--------|
|                                                                      |   | As Reported AsPreviouslyRestated in10-K/AAmendmentNo. 1 |   |   | Adjustment |   |   | As Restated |   |
| Supplemental Disclosure of Noncash Financing Activities:                  |   |   |   |   |   |   |   |   |   |
| Initial value of Class A common stock subject to possible redemption      |   | $ | 288,566,580 |   |   | $ | (288,566,580 | ) |   | $ | - |   |
| Change in value of Class A common stock subject to possible redemption    |   | $ | (366,280 | ) |   | $ | 366,280 |   |   | $ | - |   |
|                                                                           |   | Earnings Per Share for Class A common stock |       |
|---------------------------------------------------------------------------|--------|---------------------------------------------|------------|
|                                                                      |   | As Previously Reported                      |       |   | Adjustment |   |   | As Restated |   |
| For the period from August 26, 2020 (inception) through December 31, 2020 |   |                                        |       |   |   |   |   |   |   |
| Net loss                                                                  |   | $                                           | (2,269,591 | ) |   | $ | - |   |   | $ | (2,269,591 | ) |
| Weighted average shares outstanding, basic and diluted                    |   |                                        | 33,120,000 |   |   |   | (32,085,000 | ) |   |   | 1,035,000 |   |
| Basic and diluted loss per share                                          |   | $                                           | (0.00      | ) |   | $ | (0.27 | ) |   | $ | (0.27 | ) |
|                                                                           |   | Earnings Per Share for Class B common stock |       |
|---------------------------------------------------------------------------|--------|---------------------------------------------|------------|
|                                                                      |   | As Previously Reported                      |       |   | Adjustment |   |   | As Restated |   |
| For the period from August 26, 2020 (inception) through December 31, 2020 |   |                                        |       |   |   |   |   |   |   |
| Net loss                                                                  |   | $                                           | (2,269,591 | ) |   | $ | - |   |   | $ | (2,269,591 | ) |
| Weighted average shares outstanding, basic and diluted                    |   |                                        | 7,233,750  |   |   |   | - |   |   |   | 7,233,750 |   |
| Basic and diluted loss per share                                          |   | $                                           | (0.31      | ) |   | $ | 0.04 |   |   | $ | (0.27 | ) |

----

Table of Contents

| As of December 28, 2020                                                                                   |   | As Reported AsPreviouslyRestated in10-K/AAmendmentNo. 1 |        |   | Adjustment |   |        | As Restated |   |   | % Change    |   |
|-----------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|-------------|--------|------------|--------|-------------|-------------|--------|--------|-------------|--------|
| Total assets                                                                                              |   | $                                                       | 332,680,575 |   |       | $      | -           |        |   | $      | 332,680,575 |   |   |   |   |
| Total liabilities                                                                                         |   | $                                                       | 39,113,985  |   |       | $      | -           |        |   | $      | 39,113,985  |   |   |   |   |
| Class A common stock subject to possible redemption                                                       |   |                                                    | 288,566,580 |   |       |   | 42,633,420  |        |   |   | 331,200,000 |   |   |   | 14.8 | % |
| Preferred stock                                                                                           |   |                                                    | -           |   |       |   | -           |        |   |   | -           |   |   |   |   |   |
| Class A common stock                                                                                      |   |                                                    | 426         |   |       |   | (426        | )           |   |   | -           |   |   |   | -100.0 | % |
| Class B common stock                                                                                      |   |                                                    | 828         |   |       |   | -           |        |   |   | 828         |   |   |   |   |   |
| Additional paid-in capital                                                                                |   |                                                    | 6,902,066   |   |       |   | (6,902,066  | )           |   |   | -           |   |   |   | -100.0 | % |
| Accumulated deficit                                                                                       |   |                                                    | (1,903,310  | )      |       |   | (35,730,928 | )           |   |   | (37,634,238 | )      |   |   | 1877.3 | % |
| Total stockholders' equity (deficit)                                                                      |   |                                                    | 5,000,010   |   |       |   | (42,633,420 | )           |   |   | (37,633,410 | )      |   |   | -852.7 | % |
| Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit) |   | $                                                       | 332,680,575 |   |       | $      | -           |        |   | $      | 332,680,575 |   |   |   |   |   |

----

Table of Contents

----

Table of Contents

|  | ● | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; |
|--|---------|----------------------------------------------------------------------------------------------------------|
|  | ● | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for                  identical or similar instruments in markets that are not active; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | ● | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which                  one or more significant inputs or significant value drivers are unobservable. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | in whole and not in part; |
|--|---------|---------------------------|
|  | • | at a price of $0.01 per warrant; |
|--|---------|----------------------------------|
|  | • | upon a minimum of 30 days’ prior written notice of redemption; and |
|--|---------|--------------------------------------------------------------------------|
|  | • | if, and only if, the last reported sale price of Class A common stock for any 10 trading days within a 20-trading day period ending on the third trading day prior to the date on which the Company sends the                  notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A common                  stock and equity-linked securities). |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | in whole and not in part; |
|--|---------|---------------------------|
|  | • | at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless                  basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A common stock; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | if, and only if, the Reference Value equals or exceeds $10.00 per Public Share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the                  like); and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | if and only if, the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A common                  stock and equity-linked securities), the Private Placement Warrants are concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Gross proceeds                                                                     |   | $      | 331,200,000 |   |
|------------------------------------------------------------------------------------|--------|--------|-------------|--------|
| Less:                                                                              |   |   |        |   |
| Fair value of Public Warrants at issuance                                          |   |   | (17,884,800 | )      |
| Offering costs allocated to Class A ordinary shares subject to possible redemption |   |   | (17,870,300 | )      |
| Plus:                                                                              |   |   |        |   |
| Accretion on Class A ordinary shares subject to possible redemption amount         |   |   | 35,755,100  |   |
| Class A ordinary shares subject to possible redemption                             |   | $      | 331,200,000 |   |

----

Table of Contents

|                                                       |   | Fair Value Measured as of December31, 2020 |        |
|------------------------------------------------------------|--------|--------------------------------------------|-------------|
|                                                       |   | Level 1                                    |        |   | Level 2 |   |   | Level 3 |   |
| Assets:                                                    |   |                                       |        |   |   |   |   |   |   |
| Investments held in Trust Account - US Treasury securities |   | $                                          | 331,191,879 |   |   | $ | - |   |   | $ | - |   |
| Liabilities:                                               |   |                                       |        |   |   |   |   |   |   |   |   |   |
| Derivative warrant liabilities - Public warrants           |   | $                                          | -           |   |   | $ | - |   |   | $ | 18,050,400 |   |
| Derivative warrant liabilities - Public warrants           |   | $                                          | -           |   |   | $ | - |   |   | $ | 9,572,640 |   |

----

Table of Contents

|                                                   |   | As of December 28, 2020 |   |   | As of December 31, 2020 |   |
|--------------------------------------------------------|--------|-------------------------|--------|--------|-------------------------|--------|
| Option term (in years)                                 |   |                    | 1.0    |   |                    |   | 1.0 |   |
| Volatility                                             |   |                    | 20.70  | %      |                    |   | 20.90 | % |
| Risk-free interest rate                                |   |                    | 0.38   | %      |                    |   | 0.36 | % |
| Expected dividends                                     |   |                    | 0.00   | %      |                    |   | 0.00 | % |
| Probability of successful initial business combination |   |                    | 80.0   | %      |                    |   | 80.0 | % |
| Derivative warrant liabilities at August 26, 2020 (inception) |   | $      | -          |   |
|---------------------------------------------------------------|--------|--------|------------|--------|
| Issuance of Public and Private Warrants                       |   |   | 27,284,960 |   |
| Change in fair value of derivative warrant liabilities        |   |   | 338,080    |   |
| Derivative warrant liabilities at December 31, 2020           |   | $      | 27,623,040 |   |

----

Table of Contents

|                          |   | December31, 2020 |    |
|-------------------------------|--------|------------------|---------|
| Current                       |   |             |    |
| Federal                       |   | $                | -       |   |
| State                         |   |             | -       |   |
| Deferred                      |   |             |    |   |
| Federal                       |   |             | (24,357 | ) |
| State                         |   |             | -       |   |
| Change in Valuation allowance |   |             | 24,357  |   |
| Income tax provision          |   | $                | -       |   |
|                                 |   | December31, 2020 |    |
|--------------------------------------|--------|------------------|---------|
| Deferred tax assets:                 |   |             |    |
| Start-up/Organization costs          |   | $                | 8,143   |   |
| Net operating loss carryforwards     |   |             | 16,215  |   |
| Total deferred tax assets            |   |             | 24,357  |   |
| Valuation allowance                  |   |             | (24,357 | ) |
| Deferred tax asset, net of allowance |   | $                | -       |   |
|                                                          |   | December31, 2020 |   |
|---------------------------------------------------------------|--------|------------------|--------|
| Statutory federal income tax rate                             |   |             | 21.0   | % |
| Change in fair value of derivative warrant liabilities        |   |             | (3.1   | )% |
| Transaction costs allocated to derivative warrant liabilities |   |             | (9.6   | )% |
| Loss upon issuance of private placement warrants              |   |             | (7.2   | )% |
| Change in valuation allowance                                 |   |             | (1.1   | )% |
| Income Taxes Benefit                                          |   |             | 0.0    | % |

----

Table of Contents

----